Kidney Cancer

>

Latest News

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.
Toripalimab Combo Receives Chinese Approval for Advanced RCC

April 10th 2024

Toripalimab plus axitinib is now an approved regimen in China for patients with medium- to high-risk unresectable or metastatic renal cell carcinoma.

Findings from a phase 2 trial highlight an acceptable adverse effect profile and renal function with stereotactic ablative body radiotherapy in primary renal cell cancer.
Stereotactic Radiation Appears Effective in Primary Renal Cell Cancer

March 20th 2024

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.
Comparable Findings in White and Black Populations for ICI Use in Metastatic RCC

February 20th 2024

Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer
Belzutifan Improves QoL and Disease Progression Time in Advanced Kidney Cancer

January 27th 2024

Subcutaneous Nivolumab Demonstrates Noninferiority to Standard IV Dosing in ccRCC
Subcutaneous Nivolumab Demonstrates Noninferiority to Standard IV Dosing in ccRCC

January 27th 2024

More News